Amarin names Huff to lead cholesterol drug commercialization
Amarin Corp. plc, an Irish biotech with U.S. research and development headquarters in Mystic, Conn., has named Paul Huff, an industry veteran with cholesterol drug commercialization under his belt, as chief commercial officer. He will be in charge of leading the company's commercialization plan for its AMR101 cholesterol drug, aimed at lowering high triglyceride levels. The appointment coincides with Amarin's announcement of plans to open a U.S. sales and marketing headquarters in New Jersey, separate from the R&D headquarters in Connecticut.
Huff joins Amarin having served previously as vice president of marketing for Reliant Pharmaceuticals Inc., where he helped commercialize the company's Lovaza drug made for reducing triglycerides. A similar position at Kos Pharmaceuticals Inc. had Huff helping to commercialize another cholesterol drug, called Niaspan, developed to help raise HDL cholesterol.